Amount Raised
$7.5 Million
Round Type
Post-IPO Equity
LavalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it has closed a private placement of the Company's securities pursuant to the terms of a securities purchase agreement, dated September 24, 2023, by and between the Company and certain institutional and accredited investors (the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold an aggregate of 1,951,371 common shares, no par value per share, pre-funded warrants (the “Pre-funded Warrants”) to purchase up to an aggregate of 2,106,853 common shares, each at a purchase price of $1.8481 per common share or Pre-funded Warrant (less $0.0001 per Pre-funded Warrant) and accompanying common warrants (the “Common Warrants”) to purchase up to an aggregate of 2,536,391 common shares, in a private placement priced at-the-market under Nasdaq rules. The private placement closed on September 25, 2023.
Quick answer
Acasti raised $7.5 Million in a Post-IPO Equity round, dated September 26, 2023. Acasti is based in Laval, Quebec, Canada.
- How much did Acasti raise?
- Acasti raised $7.5 Million in a Post-IPO Equity round on September 26, 2023.
- What does Acasti do?
- Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
- Where is Acasti based and how big is it?
- Acasti is based in Laval, Quebec, Canada. Fundz records about 18 employees.
- Who are the decision-makers at Acasti?
- Fundz holds 1 contact at Acasti. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Acasti that raised within 45 days of this round, from Fundz verified event records.
- Forward Therapeutics raised $50M (Series A) on November 8, 2023.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Gyre Therapeutics raised $5M on October 30, 2023.
- Aligos Therapeutics raised $92M on October 25, 2023.
- Azora Therapeutics, Inc. (DE) raised $4M (Seed) on October 19, 2023.
Who to call at Acasti, and when
A new round usually means Acasti is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Acasti raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acasti, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acasti. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acasti raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Acasti raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.